Profil
Jeffrey Roger Warren served as the Chief Executive Officer of Bristol & West Plc.
He also worked as a Non-Executive Director at Oxford BioTherapeutics Ltd.
Additionally, he was a Senior Independent Non-Executive Director at Albion Venture Capital Trust PLC from 2012 to 2020.
Ehemalige bekannte Positionen von Jeffrey Roger Warren
| Unternehmen | Position | Ende |
|---|---|---|
| ALBION VENTURE CAPITAL TRUST PLC | Direktor/Vorstandsmitglied | 05.01.2020 |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Direktor/Vorstandsmitglied | 14.04.2011 |
| BRISTOL &BRISTOL&W | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Bristol & West Plc
 Bristol & West Plc Regional BanksFinance Bristol & West Plc engages in the provision of lending and financial services. It also provides savings products via various distribution channels. The company was founded on April 21, 1987 and is headquartered in Bristol, the United Kingdom. | Finance |
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Albion Venture Capital Trust PLC
 Albion Venture Capital Trust PLC Investment ManagersFinance Albion Venture Capital Trust PLC a evergreen fund invests in public and private companies located in the UK. The fund targets companies operating in the fields of health technology and services, consumer services and media services. It provides financing for early and later stage transactions. It makes follow on investments. | Finance |
